ALPS Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-99,164
| Closed | -$1.93M | – | 997 |
|
|
2018
Q1 | $1.93M | Buy |
99,164
+17,038
| +21% | +$334K | 0.02% | 214 |
|
|
2017
Q4 | $1.37M | Buy |
82,126
+8,940
| +12% | +$164K | 0.01% | 219 |
|
|
2017
Q3 | $1.49M | Buy |
73,186
+6,661
| +10% | +$127K | 0.01% | 208 |
|
|
2017
Q2 | $1.07M | Buy |
66,525
+3,079
| +5% | +$45.5K | 0.01% | 224 |
|
|
2017
Q1 | $803K | Sell |
63,446
-7,554
| -11% | -$91.2K | 0.01% | 238 |
|
|
2016
Q4 | $941K | Sell |
71,000
-23,158
| -25% | -$396K | 0.01% | 224 |
|
|
2016
Q3 | $2.23M | Sell |
94,158
-9,535
| -9% | -$256K | 0.02% | 179 |
|
|
2016
Q2 | $2.99M | Buy |
103,693
+22,043
| +27% | +$718K | 0.03% | 151 |
|
|
2016
Q1 | $2.61M | Sell |
81,650
-11,242
| -12% | -$395K | 0.03% | 143 |
|
|
2015
Q4 | $3.97M | Sell |
92,892
-20,282
| -18% | -$810K | 0.04% | 130 |
|
|
2015
Q3 | $39.8K | Buy |
113,174
+42,001
| +59% | +$1.89M | 0.04% | 126 |
|
|
2015
Q2 | $3.27M | Buy |
71,173
+35,748
| +101% | +$1.7M | 0.03% | 140 |
|
|
2015
Q1 | $1.66M | Buy |
+35,425
| New | +$1.41M | 0.01% | 157 |
|
ALPS Advisors's IPXL Position: Q2 2018 in Review
ALPS Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 99,164 shares — an estimated $1.93M sold.
ALPS Advisors first reported a position in IPXL in Q1 2015 and held it in 13 quarters. The position peaked at $3.97M in Q4 2015. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- ALPS Advisors reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- ALPS Advisors sold 99,164 Impax Laboratories, Inc. shares in Q2 2018, an estimated $1.93M.
- ALPS Advisors first reported a position in Impax Laboratories, Inc. in Q1 2015 and held it in 13 quarters.
- ALPS Advisors's Impax Laboratories, Inc. position peaked at $3.97M in Q4 2015.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on ALPS Advisors's 13F filing for Q2 2018, filed 25 Jul 2018.